Gamma Biosciences, A Life Sciences Platform Established By KKR, Announces Sale Of Mirus Bio To Merck KGaA, Darmstadt, Germany, For $600M
Portfolio Pulse from Benzinga Newsdesk
Gamma Biosciences, established by KKR, has announced the sale of its operating company Mirus Bio to Merck KGaA for $600 million in cash.
May 23, 2024 | 12:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
KKR's Gamma Biosciences has sold Mirus Bio to Merck KGaA for $600 million in cash, potentially boosting KKR's financials and investment returns.
The sale of Mirus Bio for $600 million in cash is a significant transaction for KKR, likely to positively impact its financials and investment returns in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80